291 related articles for article (PubMed ID: 31675173)
1. Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation.
El-Serafi I; Remberger M; Ringdèn O; Törlén J; Sundin M; Björklund A; Winiarski J; Mattsson J
Clin Transl Sci; 2020 Mar; 13(2):293-300. PubMed ID: 31675173
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome.
Nagler A; Labopin M; Berger R; Bunjes D; Campos A; Socié G; Kröger N; Goker H; Yakoub-Agha I; Shimoni A; Mohty M; Rocha V
Bone Marrow Transplant; 2014 May; 49(5):628-33. PubMed ID: 24535127
[TBL] [Abstract][Full Text] [Related]
3. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
Kashyap A; Wingard J; Cagnoni P; Roy J; Tarantolo S; Hu W; Blume K; Niland J; Palmer JM; Vaughan W; Fernandez H; Champlin R; Forman S; Andersson BS
Biol Blood Marrow Transplant; 2002; 8(9):493-500. PubMed ID: 12374454
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.
Rezvani AR; McCune JS; Storer BE; Batchelder A; Kida A; Deeg HJ; McDonald GB
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1033-9. PubMed ID: 23583825
[TBL] [Abstract][Full Text] [Related]
5. Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Bognàr T; Bartelink IH; Egberts TCG; Rademaker CMA; Versluys AB; Slatter MA; Kletzel M; Nath CE; Cuvelier GDE; Savic RM; Dvorak C; Long-Boyle JR; Cowan MJ; Bittencourt H; Bredius RGM; Güngör T; Shaw PJ; Ansari M; Hassan M; Krajinovic M; Hempel G; Marktel S; Chiesa R; Théoret Y; Lund T; Orchard PJ; Wynn RF; Boelens JJ; Lalmohamed A
Transplant Cell Ther; 2022 Apr; 28(4):196-202. PubMed ID: 35065280
[TBL] [Abstract][Full Text] [Related]
6. Targeted-dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial.
Esteves I; Santos FPS; Ribeiro AAF; Seber A; Sugawara EK; Sobrinho JJDN; Barros JC; Oliveira JSR; Fernandes JF; Hamerschlak N; Andersson BS; de Lima M; Kerbauy FR
Hematol Oncol; 2020 Dec; 38(5):773-781. PubMed ID: 32779746
[TBL] [Abstract][Full Text] [Related]
7. Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT.
Cantoni N; Gerull S; Heim D; Halter J; Bucher C; Buser A; Tsakiris DA; Passweg J; Tichelli A; Stern M; Gratwohl A
Bone Marrow Transplant; 2011 Mar; 46(3):344-9. PubMed ID: 20548339
[TBL] [Abstract][Full Text] [Related]
8. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
Satwani P; Bhatia M; Garvin JH; George D; Dela Cruz F; Le Gall J; Jin Z; Schwartz J; Duffy D; van de Ven C; Foley S; Hawks R; Morris E; Baxter-Lowe LA; Cairo MS
Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471
[TBL] [Abstract][Full Text] [Related]
9. Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.
Abate ME; Paioli A; Cammelli S; Cesari M; Longhi A; Palmerini E; Ferrari S; Carretta E; Picci P; Piscaglia F
Bone Marrow Transplant; 2018 May; 53(5):591-599. PubMed ID: 29335623
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
O'Donnell PH; Artz AS; Undevia SD; Pai RK; Del Cerro P; Horowitz S; Godley LA; Hart J; Innocenti F; Larson RA; Odenike OM; Stock W; Van Besien K
Leuk Lymphoma; 2010 Dec; 51(12):2240-9. PubMed ID: 20919852
[TBL] [Abstract][Full Text] [Related]
11. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.
Lewis C; Kim HT; Roeker LE; Cutler C; Koreth J; Nikiforow S; Armand P; Gootpu M; Romee R; Glotzbecker B; Nageshwar P; Antin JH; Alyea EP; Richardson P; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2020 Mar; 26(3):529-539. PubMed ID: 31678537
[TBL] [Abstract][Full Text] [Related]
12. Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT.
Berger K; Schopohl D; Rieger C; Ostermann H
Support Care Cancer; 2015 Dec; 23(12):3447-54. PubMed ID: 25773673
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation.
Goekkurt E; Stoehlmacher J; Stueber C; Wolschke C; Eiermann T; Iacobelli S; Zander AR; Ehninger G; Kröger N
Anticancer Res; 2007; 27(6C):4377-80. PubMed ID: 18214047
[TBL] [Abstract][Full Text] [Related]
14. Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation.
Seifert C; Wittig S; Arndt C; Gruhn B
J Cancer Res Clin Oncol; 2015 May; 141(5):877-85. PubMed ID: 25335953
[TBL] [Abstract][Full Text] [Related]
15. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
16. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
17. Possible correlation of sirolimus plasma concentration with sinusoidal obstructive syndrome of the liver in patients undergoing myeloablative allogeneic hematopoietic cell transplantation.
Kiel PJ; Vargo CA; Patel GP; Rosenbeck LL; Srivastava S
Pharmacotherapy; 2012 May; 32(5):441-5. PubMed ID: 22499411
[TBL] [Abstract][Full Text] [Related]
18. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
[No Abstract] [Full Text] [Related]
19. Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy.
Kuwatsuka Y; Kohno A; Terakura S; Saito S; Shimada K; Yasuda T; Inamoto Y; Miyamura K; Sawa M; Murata M; Karasuno T; Taniguchi S; Nagafuji K; Atsuta Y; Suzuki R; Fukumoto M; Naoe T; Morishita Y;
Cancer Sci; 2012 Sep; 103(9):1688-94. PubMed ID: 22631696
[TBL] [Abstract][Full Text] [Related]
20. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
Lee JW; Kang HJ; Kim S; Lee SH; Yu KS; Kim NH; Jang MK; Kim H; Song SH; Park JD; Park KD; Shin HY; Jang IJ; Ahn HS
Biol Blood Marrow Transplant; 2015 Jan; 21(1):190-5. PubMed ID: 25255163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
